American Society of Hematology

ASH Meeting on Hematologic Malignancies

Hear top experts in hematologic malignancies discuss the latest developments in clinical care.

Learn more

The Year's Best

Thoughtful commentaries on several of the most meaningful hematologic breakthroughs of 2014, written by editors of The Hematologist and selected guest experts.

Learn more

CME Credit and Certificate of Attendance

Obtain CME credit and a certificate of attendance for the 56th ASH Annual Meeting by April 17, 2015.

Learn more

Protect Medical Research

Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to medical research.

Take action
Find a Hematologist

Find a Hematologist

Search a database of practicing hematologists in your area.

Learn more
Support Hematology

ASH Foundation

Help move hematology forward by supporting research, career development, and quality care and education programs.

Learn more
Join ASH

ASH Membership

Become part of a global network of more than 16,000 hematologists working to conquer blood diseases.

Learn more
View all press releases
  • New Oncology Care Model Released by Center for Medicare and Medicaid Innovation

    On February 12, 2015, the Center for Medicare and Medicaid Innovation (CMMI) revealed the opportunity for practices to participate in a payment model dedicated the care of patients with cancer.  Although there will be additional details to finalize, CMMI would like practices to express interest in participating in the model by April 23, 2015, even though it will not begin paying with this method until 2016.  Click on the headline to read more.

  • ASH Comments on FDA Draft Guidance for Laboratory Developed Tests

    On January 30, ASH submitted comments on the Food and Drug Administration's (FDA) Draft Guidance  on Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs).  The Guidance Document proposes that FDA assert its regulatory authority and increase oversight of LDTs.  Click on the link above to read more about ASH's comments.

  • ASH Comments on NIH Single IRB Policy

    On January 28, The American Society of Hematology (ASH) submitted comments  on the National Institutes of Health's (NIH) Draft Policy to promote the use of a single Institutional Review Board (IRB) of record for domestic sites of multi-site clinical studies funded by NIH.  The draft NIH policy proposes that all NIH-funded, multi-site studies carried out in the United States, whether supported through grants, contracts, or the NIH intramural program, should use a single IRB.  Read more to learn about ASH's stance on the policy.

  • ODAC Recommends Approval of First Biosimilar Drug

    The Oncologic Drugs Advisory Committee (ODAC) of the Food and Drug Administration (FDA) recommended the approval of the first application for a biosimilar drug on January 7.  The panel recommended that FDA approve the application for a biologic agent similar to filgrastim.  This drug would be used for a number of applications in hematology.

View all policy news
  • JAK2 V617F 10 Years Later: Dr. Dameshek's Prophecy Fulfilled

    For more than a century, clinicians have recognized myeloproliferative neoplasms (MPNs) as disorders that are characterized by expansion of different myeloid lineages, with important clinical sequelae. However, the seminal insight into these diseases came when Dr. William Dameshek wrote in an editorial in Blood that MPNs share specific clinical features including thrombosis, bleeding, and an increased risk of progression to leukemia.

  • ASH Program Helps Bring Nigerian Hematologist to Roswell Park Cancer Institute for Training

    Tamunomieibi Wakama, MD, is a visiting physician at Roswell Park Cancer Institute (RPCI) thanks to a Visitor Training Program (VTP) grant from ASH that was awarded to Vishala Neppalli, MD, assistant professor of oncology in the Department of Pathology & Laboratory Medicine at RPCI.

  • JAK Inhibitors: Life is Good, Stable is Good

    As we opened the first three clinical trials of JAK inhibitors in the summer of 2007 at MD Anderson Cancer Center, there was palpable enthusiasm and much anticipation among both physicians and patients. I vividly remember my first patient who enrolled in the phase I/II trial of ruxolitinib (the very first person in the world to be treated with a JAK inhibitor, in fact). He was an older man with massive splenomegaly and hepatomegaly resulting is ascites and swelling of the legs, severely compromising his ambulation and quality of life.

  • New Drugs to Match My New Genes? A Look Back at the 56th ASH Annual Meeting

    New Drugs to Match My New Genes? A Look Back at the 56th ASH Annual Meeting For us hematologists, the first full weekend in December is typically blacked out in our calendars. During this sacred time, ASH hosts its annual meeting for anyone interested in the basic science, clinical

View all Hematologist articles